See more : ATMA Participações S.A. (ATMP3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Beam Therapeutics Inc. (BEAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beam Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Poema Global Holdings Corp. (PPGH) Income Statement Analysis – Financial Results
- Synel M.L.L Payway Ltd (SNELF) Income Statement Analysis – Financial Results
- Noble Corporation Plc (NBLWF) Income Statement Analysis – Financial Results
- Kaname Kogyo Co.,Ltd. (6566.T) Income Statement Analysis – Financial Results
- Procyon Corporation (PCYN) Income Statement Analysis – Financial Results
Beam Therapeutics Inc. (BEAM)
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 377.71M | 60.92M | 51.84M | 24.00K | 18.00K | 0.00 | 0.00 |
| Cost of Revenue | 437.38M | 22.58M | 16.44M | 103.18M | 5.41M | 650.00K | 11.00K |
| Gross Profit | -59.67M | 38.34M | 35.40M | -103.16M | -5.39M | -650.00K | -11.00K |
| Gross Profit Ratio | -15.80% | 62.94% | 68.29% | -429,812.50% | -29,938.89% | 0.00% | 0.00% |
| Research & Development | 437.38M | 311.59M | 387.09M | 103.18M | 54.62M | 33.87M | 5.86M |
| General & Administrative | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -71.00K | -10.04M | 378.00K |
| Operating Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Cost & Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Interest Income | 0.00 | 15.30M | 9.00K | 1.57M | 2.49M | 292.00K | 0.00 |
| Interest Expense | 0.00 | 15.30M | 9.00K | 1.57M | 187.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 20.01M | 22.58M | 16.44M | 9.47M | 5.41M | 650.00K | 11.00K |
| EBITDA | -156.47M | -324.33M | -392.47M | -128.03M | -71.65M | -45.09M | -7.99M |
| EBITDA Ratio | -41.43% | -659.03% | -799.13% | -269,270.83% | -384,644.44% | 0.00% | 0.00% |
| Operating Income | -176.49M | -338.48M | -392.47M | -132.76M | -75.15M | -45.74M | -7.88M |
| Operating Income Ratio | -46.73% | -555.61% | -757.01% | -553,166.67% | -417,522.22% | 0.00% | 0.00% |
| Total Other Income/Expenses | 45.32M | 78.30M | 21.83M | -61.83M | -3.17M | -71.00M | -122.00K |
| Income Before Tax | -131.16M | -260.18M | -370.64M | -194.59M | -78.33M | -116.74M | -8.00M |
| Income Before Tax Ratio | -34.73% | -427.08% | -714.91% | -810,800.00% | -435,144.44% | 0.00% | 0.00% |
| Income Tax Expense | 1.37M | 3.41M | -29.28M | 61.83M | 116.00K | -71.00M | 500.00K |
| Net Income | -132.53M | -263.59M | -341.36M | -256.42M | -78.44M | -115.26M | -8.00M |
| Net Income Ratio | -35.09% | -432.68% | -658.44% | -1,068,433.33% | -435,788.89% | 0.00% | 0.00% |
| EPS | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| EPS Diluted | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| Weighted Avg Shares Out | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
| Weighted Avg Shares Out (Dil) | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
Analysts see over 50% gains in these 2 mid-cap biotech stocks
3 Biotech Stocks to Buy on the Dip: February 2024
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Why Beam Therapeutics Stock Zoomed 17% Higher Today
Source: https://incomestatements.info
Category: Stock Reports